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Azobenzene photocontrol of peptides
and proteins
Robert J. Mart and Rudolf K. Allemann*
The last few years have witnessed significant advances in the use of light as a stimulus to control
biomolecular interactions. Great eﬀorts have been devoted to the development of genetically encoded
optobiological and small photochromic switches. Newly discovered small molecules now allow
researchers to build molecular systems that are sensitive to a wider range of wavelengths of light than
ever before with improved switching fidelities and increased lifetimes of the photoactivated states.
Because these molecules are relatively small and adopt predictable conformations they are well suited as
tools to interrogate cellular function in a spatially and temporally contolled fashion and for applications in
photopharmacology.
Introduction
The development of tools to control biomacromolecular func-
tion with light oﬀers the potential to change the properties of
defined molecules in biological systems with minimal pertur-
bance to the rest of the system. This article presents highlights
of current developments alongside their historical context to
complement recent reviews of this field that have covered mole-
cular switches,1,2 light-responsive materials,3,4 optogenetic tools5–7
and biological control.8
Principles of photocontrol
Protein–protein interaction networks allow cells to integrate
chemical signals about their state and environment and respond
by regulating protein production, enzyme activities and meta-
bolism to suit their circumstances. Photocontrol of peptides,
proteins or drugs provides a non-invasive way to perturb these
networks to investigate their effect or cause a defined outcome.
Achieving photocontrol requires the addition to a photoresponsive
element to a protein, peptide or drug in such a way that its
photochromism alters the properties of the conjugated mole-
cule (Fig. 1). Some photochromic molecules respond to light by
making or breaking bonds2 leading to changes in their geo-
metry and polarity, but the increased degrees of freedom of one
of the states can lessen conformational control. In contrast,
molecules capable of acting as photoswitches that interconvert
between E and Z double bonds offer highly predictable light-
state structural properties. In such molecules isomerisation is
induced by absorption of a photon to generate an electronically
excited state, in which the barrier to rotation between the E and
Z forms is reduced. Decay to the electronic ground state
re-establishes the barrier, kinetically trapping the thermally
less stable isomer. The barrier height relative to the available
thermal energy then determines the rate of relaxation to the
thermodynamically more stable isomer. Although stilbenes,9–12
hemithioindigos,11–23 thioxopeptides,24–28 selenoxopeptides,29
diarylethenes30,31 and acylhydrazones32 and rhodopsin-like
molecules33,34 have been used as switches, azobenzenes35,36
currently offer the largest range of activation wavelengths and
photoactivated state stabilities. In azobenzene-derived photo-
switches rotation around the central double bond is trans-
mitted with high fidelity through the rigid rings resulting in a
predictable distance changes, particularly between substituents
on the para positions. Azobenzenes are readily synthesised
either non-symmetrically by the condensation of a nitroso-aryl
compound and anilines or symmetrically by in situ nitroso for-
mation under oxidising conditions. Classical aromatic chemistry
allows access to various photo-switching wavelengths and
thermal reversion characteristics tailored to suit a particular
Fig. 1 Photochromicmolecules can influence biomolecules by stabilising or
destabilising their interacting conformations. This approach can be applied
to (a) peptides corresponding to elements of protein–protein interaction
partners, (b) loops or domain interfaces of proteins themselves, (c) tethered
ligands to control ion channels or (d) incorporated into existing non-
photochromic drugs.
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application (Fig. 2). The choice of azobenzene derivative is
dependent on its spectral properties, the ratio of isomers at its
photostationary state, its solubility, its resistance to reduction and
the distance between the intended points of control.
Azobenzene photoswitches
Improving photophysical properties
Photoswitches can be conveniently linked to proteins by selec-
tive reactions with the thiol side chains of cysteine residues.
Surface accessible cysteine side chains react readily with e.g.
para-haloacetamide substituted azobenzenes such as iodoacet-
amidoazobenzene (1) (Fig. 3).37 Early work demonstrated that
with pairs of cysteines in i,i + 4 or i,i + 7 spacings along a
peptide chain, an a-helical conformation is stabilised by the
Z-isomer of 1 while the E-isomer is a-helix stabilising for i,i + 11
spacings.38 The water-soluble azobenzene 2 expanded the
scope of this technique and allowed protein–protein, protein–
DNA and protein–RNA interactions to be controlled through
a-helical motifs.39,40 While the excitation wavelengths in the
UV-range limited the biological applications of these early
azobenenzene photoswitches, new photochromic molecules
that absorb at higher wavelengths have recently been developed
and can be actuated with non-toxic visible light.41
Introduction of ortho-amino groups yielded azobenzenes
(3–8) with a wide range of photochemical properties (Fig. 4).42
Most have significantly red-shifted absorbance spectra (445–470 nm),
but protonation of the amines produces forms that diminish
the double bond character of the azo bond and lead to shorter
relaxation half-lives of between 0.7 seconds and 5 minutes
compared toB30 minutes for 2. A red-shifted p–p* absorbance
maximum was also observed with a pair of ortho-methoxy sub-
stituents (9), but the introduction of four methoxy-groups ortho
to the azo-bond (10) produced different properties (Fig. 5).43
The absorbance spectrum of Z-10 reveals a 36 nm shift of its
n–p* band compared to E-10 (Fig. 6). This separation of the
n–p* bands permits green light irradiation (530 to 560 nm) to
convert E-10 toB80% Z-10, eliminating the need for damaging
UV light altogether. Furthermore, the relaxation half-life of Z-10 is 12
hours in buffer at 40 1C, making it ideal for biological applications.
However, the electron donating effect makes 10 vulnerable to
reduction with a half-life of 90min in glutathione-containing buffers
that reproduce the cytosolic reduction potential.43 Replacing the
methoxy groups with methylthioethers in 11 retained the separation
between the n–p* transitions of the isomers, which were red shifted
and strengthened compared to 10, but model bioconjugates of 11
had short half lives of the light activated state (3.3 minutes
at 37 1C).44 In contrast, the extended analogue Z-12 had a thermal
reversion half-life of several hours in water at 37 1C.45
Given the destabilising eﬀect of amino (rather than amide)
substituents of 3–8 on their Z isomers, it is understandable that
installing piperidine as a more flexible spacer in the para position
resulted in Z-13 having a half life of less than 4 seconds in buffer
at 25 1C.46
However, when this motif was combined with tetra-ortho-
methoxy substitution, the resulting molecule (14) displayed
Fig. 2 Substituents can alter the photophysical properties of azobenzenes
with wavelength ranges between 300 and 630 nm and provide the means
to tune the half-life of the thermodynamically less stable Z-isomer.
Fig. 3 Bis-para-(iodoacetamido)azobenzene (1) reacts with the sidechains
of a pair of cysteines of a peptide to form a photo-responsive ‘staple’. The
addition of sulfonic acid groups render 2 water-soluble.
Fig. 4 Amino-substituted azobenzenes with red-shifted p–p* transitions
and rapid relaxation.
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unexpected properties.47 With methoxy and amino substituents
in place the pKa of the protonated form of 14 rises to the
physiologically accessible value of 7.548 and the absorption
spectrum of the azonium species is broad enough for irradia-
tion with 630 nm light to cause isomerisation. This eﬀect was
ascribed to a diﬀerence in pKa values between the protonated
states of E-14 and Z-14, with the azonium species stabilised by a
hydrogen bond in E-14 but not in Z-14 (Fig. 7).
Therefore, at pH 7, 14 is protonated, photoswitches and then
deprotonates. Whilst the half-life of Z-14 is only 13 seconds,
it can reliably and repeatedly be photoswitched by red light in the
presence of whole blood, although it is sensitive to reduction by
glutathione.47 A second generation of azonium ion precursors
(Fig. 8) were designed to determine the optimal methoxy substitu-
tion pattern to donate electrons to the ring without sterically
hindering azonium ion formation.48 These eﬀorts resulted in 15,
which absorbs significantly at 650 nm. However, themetamethoxy
Fig. 6 UV/visible spectra of 10 in dimethylsulfoxide show the separation
of the n–p* bands at 450 and 500 nm. The separation is less pronounced
in water, but bidirectional visible light switching is still possible. Reprinted
with permission from Beharry et al., J. Am. Chem. Soc., 2011, 133, 19684.
Copyright 2011 American Chemical Society.
Fig. 7 The combination of tetra-ortho methoxy ether and para amino
substitution increases the pKa of the diazo bond, so that azonium species
are formed at neutral pH. However, the pKa of E-14 is approximately
1.5 units lower, resulting in deprotonation and slower relaxation to Z-14
than would be expected from the azonium ion.
Fig. 5 Tetra-ortho ether or thioether substitution has the beneficial eﬀect
of shifting the n–p* transition bands so that at certain wavelengths the
absorption spectra of the E- and Z-isomers do not overlap, allowing visible
light switching. Extended azobenzenes may either be used with more
widely spaced cysteine sidechains or to increase the change in end-to-end
distance to provide greater photocontrol.
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group increases steric hindrance and forces the piperazine ring
to rotate into a conformation that is less able to stabilise
azonium ion formation, reducing the apparent pKa to 2.6. This
eﬀect is alleviated in 16 by the less bulky bicyclic pyrrollidine
substituent and the apparent pKa is increased to 5.4. The absorp-
tion spectrum of 16 stretches into the near IR region with
significant absorbance up to 750 nm.
Electron rich azobenzenes can support protonation prior to or
concomitant with nucleophilic attack by thiols and are vulnerable
to reduction by glutathione. In contrast, tetra-ortho-halogen sub-
stituents (17) including tetra-ortho-fluoro49 and chloro variants45
are all resistant to glutathione reduction. Tetra-ortho-fluorodi-
para-bromo azobenzene 18 has a clear (42 nm) separation
between the n–p* transitions of its E and Z isomers, which allows
visible light switching (Fig. 9).49 A mildly electron releasing group
in the para position (17a) reduced the n–p* band separation to
22 nm compared to 18, whilst a more electron withdrawing ester
substituent (19) increased it to 50 nm. Detailed studies of
fluorinated azobenzene derivatives with symmetrical or non-
asymmetrical rings and various electron withdrawing groups in
the para-position including fluorine, esters, nitriles and amides
were carried out. Symmetrical (20) or non-symmetrical (21)
difluoro azobenzenes (Fig. 10) exhibited a smaller (28–32 nm)
n–p* band separation than 18 (42 nm), but the presence of
further additional fluorine atoms did not result in increased
separation in hexa-, octa- or deca-fluorinated azobenzenes
(36–43 nm).50 Introduction of a symmetric pair of more elec-
tron withdrawing trifluoromethyl groups in the ortho positions
decreased the n–p* band separation, an effect attributed to the
increased steric demand of this substituent resulting in the
E-isomers phenyl rings not being coplanar. This reduction in
conjugation in the ground state is likely to reduce the differ-
ence in energy and hence the n–p* band separation between the
E- and Z-isomers. Time dependant density functional theory
calculations qualitatively reproduced the spectral properties for
this series of compounds and further modelling suggested that
the extended half-lives of their Z isomers are a consequence of
the dipole moments in the transition states.50 Tetra-ortho-chloro
azobenzene 17b had a similar n–p* band separation (20 nm) to
17a (22 nm) and was shown to photoswitch under irradiation by a
635 nm LED.45 Rapid reversion to E-17b was conveniently induced
by irradiation with 450 nm light and neither isomer of 17b was
degraded by exposure to 10 mM reduced glutathione. When the
chloroacetamido analogue of 17b was attached to a test peptide, a
thermal reversion half-life of 3.5 hours was observed at 37 1C.
Subsequently, 17b was conjugated to a D-peptide labelled
with fluorescein and microinjected into zebrafish embryos.45
Photoswitch-induced quenching of the fluorophore51 was possible
for 30 hours with no obvious ill-effects (Fig. 11).45
This system represents the current state of the art for a slow
cycling switch in that it is stable against reductive and cytosolic
reduction and oﬀers the capability of bi-directional, visible-light
switching in vivo. Further developments in slow-cycling photo-
switches have been driven by potential uses for molecules that
can respond to infrared activation to which the human body is
mostly transparent. Such switches could be activated at defined
points in 3D space using multiphoton techniques.
Two-photon photoswitching had previously been reported
to be eﬀective for 1 in blood lysates52 but not for tetra-ortho-
methoxy dyes.45 However, a slightly modified tetra-ortho-fluoro
Fig. 8 Moving one methoxy group to the meta position maintains the
electron rich nature of the azobenzene ring system, but removes steric
congestion from the azonium ion formed on protonation.
Fig. 9 Tetra-ortho halogen substituents separate the n–p* transition
energies of E and Z isomers, impart resistance to glutathione reduction
and lead to long lived Z-isomers.
Fig. 10 Symmetrical and non-symmetrical difluoroazobenzenes used to
examine the origins of the n–p* band shifts and extended Z-isomer half-lives.
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azobenzene (22) was found to have a two-photon cross-section
seven times greater than azobenzene alone; two-photon excitation
of the p–p* band was possible at 640 or 720 nm.53 Installation of a
larger aromatic system with extended conjugation to act as an
antennae complex yielded 23 (Fig. 12), which can be converted to
Z-23 by 510 nm light and back to E-23 by two-photon absorption
at 750 nm.54
Another series of photoswitches employs diﬀerent types of
bridged azobenzenes (Fig. 13).55–58 The bridge has the effect of
reversing the normal thermodynamic preference for the E-isomer
so that 24 adopts almost exclusively the Z-form in its thermal
equilibrium state. 24 is converted to >90% of the E-form on
irradiation with 370–400 nm light. Reversion to Z-24 can be
achieved with irradiation with 480–550 nm light. When a chloro-
acetimido analogue of 25 was attached to a test peptide, a
photostationary state of 70% E-25 was formed upon irradiation
with 407 nm light.59 Thermal relaxation from the E to the Z form
occurred with a half-life of 8.3 hours at 20 1C, but reversion could
also be driven with 518 nm light irradiation. Whilst Z-25 was
completely resistant to glutathione reduction, E-25 degraded with
a half-life of approximately 3 hours. A different ring substitution
position resulted in 26, whose n–p* transitions were separated
by almost 90 nm (Z-26: 404 nm, E-26: 490 nm) although only
53% E-26 was present in the photostationary state.60 Other
examples of constrained azobenzenes are found in structures
containing a borodifluoride bridge (27). The switching wave-
lengths for these molecules are strongly red shifted (570 nm)
compared to conventional azobenzenes.61 Electron donating
substituents can be used to push red absorbing 28 (630 nm)
further towards the IR range in 29 (710 nm). An additional
methoxy substituent ortho to the azo substituent in 30 caused a
blue-shift (640 nm) because its steric demands twisted the
phenyl ring out of the plane of the azo bond, thereby reducing
its electronic influence (Fig. 14).62
New incorporation and conjugation approaches
Thiol–ene reactions are gaining popularity for bioorthogonal
functionalisation of peptides and proteins.63 The vinyl azo-
benzene amino acid 31 was incorporated into peptides by
conventional solid phase synthesis and, when an i + 4 cysteine
residue and an appropriate photoinitiator were present, irradia-
tion with 360 nm light caused isomerisation and a thiol–ene
Fig. 11 (a) Fluorescence image of a zebrafish embryo (early pharyngula
stage/B30 hours post fertilisation) containing the fluorescent reporter
peptide cross-linked with 4. (b) Measurements of fluorescence intensity at
the zones indicated by black boxes in (a), as a function of time during blue
light irradiation. A change in fluorescence emission was seen only if the
peptide was first switched with red light (indicated by red bars). No pre-
irradiation with red light (indicated by black bar) before blue light produces
no exponential (switching) transient, only a background slope due to
fluorescein reporter photobleaching. (c) Fluorescence image of a zebrafish
embryo (B30 hours post fertilisation) containing the fluorescent reporter
peptide without a photoswitch. (d) Measurement of fluorescence intensity of
the nonswitchable peptide as a function of time during blue-light irradiation
after preirradiation with red light as in (b). Adapted with permission from
Samanta, et al., J. Am. Chem. Soc., 2013, 135, 9777. Copyright 2013 American
Chemical Society.
Fig. 12 Tetra-ortho-fluoro substitution increases the two photon absorp-
tion cross section compared to azobenzene itself. A two photon antennae
complex is excited, then transfers energy to the azobenzene.
Fig. 13 The conformational constraints applied to bridged azobenzenes
make their Z-isomers their thermodynamic ground states. Many bridged
azobenzenes have very large separations between the n–p* band s of the
E and Z isomers. Elements adapted with permission from Siewertsen, et al.,
J. Am. Chem. Soc., 2009, 131, 15594. Copyright 2009 American Chemical
Society.
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click reaction between the cysteine sulfur and the pendant vinyl
group.64 Consequent oxidation resulted in intramolecular cross-
linking via a sulfone. Genetic code expansion can be used to
introduce 31 into proteins expressed in E. coli or mammalian
cells.65 Azobenzene 32 (Fig. 15) can also be incorporated into
expressed proteins; its pentafluoro ring is electrophilic enough
to undergo nucleophilic aromatic substitution by a proximal
cysteine.66 The fluorine atoms of 32 provide sufficient n–p* band
separation for bidirectional switching with 540 nm and 470 nm
light to generate B70% of the desired isomer in the photo-
stationary state. This switch was incorporated into calmodulin
with an orthogonal tRNA synthetase. Whilst a degree of side
reaction with glutathione was noted, cyclisation proceeded smoothly
to give a visible light responsive calmodulin with distinct binding
affinities for neuronal nitric oxide synthase under green and
blue light irradiation. Thiol–ene chemistry was also investigated to
introduce a bifunctional glycosylated azobenzene photoswitch.67
Using 2,2-dimethoxy-2-phenylacetophenone as a photoinitiator
caused 33 to react with glutathione in 70% yield (Fig. 16).
Staudinger ligations can be used to selectively functionalise
synthetic biomolecules containing azide groups incorporated
for in situ bioorthogonal labelling. The diphenylphosphoryl
azobenzene 34 performs a variation of the Staudinger ligation,
intramolecularly capturing the phosphazene intermediate formed
by reaction of the phosphine with an azide-containing peptide.
The resulting conjugate has a p–p* absorption maximum at
500 nm, but the reaction is relatively slow and the Z-isomer is
short lived (0.5 ms) (Fig. 17).68
In vitro translation and expanded genetic code techniques
have been used to create a library of peptides containing the
azobenzyl-lysine 35 (Fig. 18).69 By suppressing the stop codon and
conducting the reaction at low temperature, neither the nascent
peptide nor the coding mRNA dissociate from the ribosome.
Streptavidin-coated beads were placed in the solution in the dark
and the beads were washed and exposed to UV light, which
resulted in dissociation of the peptide–ribosome–mRNA complex.
The complexes were recovered, the mRNA dissociated and subjected
Fig. 14 Borodifluoride bridged azobenzenes are strongly red shifted and
the half-lives of the Z isomers are strongly aﬀected by dissolved oxygen.
Elements adapted with permission from Yang, et al., J. Am. Chem. Soc.,
2012, 134, 15221 (Copyright 2012 American Chemical Society) and
Yang, et al., J. Am. Chem. Soc., 2014, 136, 13190.
Fig. 15 A vinyl azobenzene (31) capable of intramolecular thiol–ene
cyclisation with an appropriately placed thiol–ene sidechain and a penta-
fluoroazobenzene (32) whose para fluoro group can be displaced by a
thiolate anion.
Fig. 16 Glycoazobenzene derivative for conjugation thiol–ene reactions.
Fig. 17 Diphenylphorhinylazobenzene 34 can be used to introduce
a pendant ‘push–pull’ azobenzene into peptides by Staudinger ligation
chemistry.
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to amplification by reverse transcriptase polymerase chain
reaction; this identified peptide sequences that bound strepta-
vidin 2.5-fold weaker in their photostationary state than in the
dark. Libraries of peptides have also been generated using phage
display.70 Peptides containing i,i + 7 spaced cysteines were
expressed in E. coli, reduced with resin-bound tris-carboxyethyl-
phosphine and treated with 2. Although the overall yield of
modification with 2 was only 50%, peptides were identified
with up to 22-fold decreases in affinity for streptavidin in their
pure dark and light states. A later study also used i,i + 7 spaced
cysteine residues alkylated with 2 and discovered peptides that
had a greater affinity in for streptavidin in the light state with
the best example found to bind 3-fold more tightly.71
Selected applications
Control of nucleic acid binding peptides
Transcription factors act as ‘master switches’ in cells for the
expression of genes in response to environmental cues. As such
they are key targets to modulate downstream processes. Many
common DNA binding motifs contain a-helices, which make
direct and indirect contacts with the bases in the major groove
of DNA. Such helices are often unstructured in the absence of
DNA or when isolated from the rest of the protein, but are
stabilised through interaction with other structural elements.
Recognition helices in homeodomains, for instance, rely on a
helix-turn-helix motif for stability (Fig. 19). The DNA recognition
helix from the engrailed homeodomain has been modified to
incorporate two i,i + 11 spaced cysteine residues to accommodate
2.72 When the peptide is folded into an a-helix, the intra-cysteine
spacing matches the length of E-2 so that the cross-linked peptide
is strongly helical and binds to target DNA 25 times more strongly
than a control peptide without 2. Irradiation to form Z-2 dimin-
ished the DNA binding aﬃnity 18-fold.
Basic helix-loop-helix proteins such as the transcription
factor MyoD bind to DNA as homodimers (Fig. 20). The DNA-
binding region is unstructured in the absence of DNA but adopts
an a-helical conformation when it contacts the DNA. The recog-
nition helix was modified to include i,i + 7 spaced cysteine
residues and reacted with 2. The photo-activated state of the
cross-linked protein not only bound DNA with an apparent
dissociation constant for the complex three orders of magnitude
higher than for the uncrosslinked protein, equivalent to a 60-fold
decrease in the half-maximal binding concentration, but also
displayed a significant increase in the specificity for its cellular
target DNA.73
bZIP proteins form a diﬀerent family of transcription factors
that rely on a-helical structures. They contain discrete DNA-
binding and leucine zipper regions. DNA binding requires
dimerization through the formation of a coiled coil (Fig. 21)
so that photocontrol can be exerted through the leucine zipper,
leaving the DNA-binding region unchanged. i,i + 7 spaced
cysteines were used to create a GCN4-bZIP peptide, which reacted
with 2 to give a photoswitchable DNA-binding peptide with
increased a-helicity and a 20-fold decrease in dissociation con-
stant towards a DNA target after irradiation.74
Similar methodology was also eﬀective in controlling of the
cyclic AMP response element-binding protein (CREB).75 Photo-
control of transcription in live cells was achieved by a modified
bZIP helix with i,i + 7 spaced cysteines and a pair of additional
acidic heptad repeats at its N-terminus.76 Once crosslinked with
2 and introduced into HEK293T cells alongside reporter DNA
this molecule (0.1 to 1.2 mM) was able to alter the expression
level 2-fold upon irradiation (Fig. 22).
In a second approach to controlling the bZIP family, an
azobenzene linker (36) was bound to two DNA-binding helices
Fig. 18 Azobenzyl-lysine, a readily synthesised amino acid with a pendant
azobenzene in its sidechain.
Fig. 19 Cartoon of the engrailed homeodomain DNA binding helix in the
major groove of its target DNA and its N-terminal extension (red), which
contacts the minor grove of the DNA (left) with two short a-helices (cyan)
that stabilise it. The stabilising role of these a-helices can be replaced by
introducing a pair of cysteine residues whose sidechains project opposite
the DNA binding face to react with 2.
Fig. 20 Cartoon illustrating the use of 2 to control the conformation of
the DNA recognition a-helix of MyoD.
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by forming thioethers with cysteine residue side chains (Fig. 23).77
When the azobenzene was switched into the Z-conformation
these helices aligned scissor-like into the major groove of a
DNA strand and bound DNA 60–70 times more strongly than in
the dark state. Single stranded RNA presents a greater variety of
binding geometries than double stranded DNA because of its
propensity to adopt different knot and loop structures. Nevertheless,
good photocontrol of RNA binding was achieved using a peptide
derived from the HIV1 Rev response element (RRE)78 crosslinked
with 1 for both i,i + 7 and i,i + 11 spacings.
Control of protein–protein interactions
Although many examples of controlling the structure of
b-hairpins79–86 and cyclic peptides87–94 are known, light is most
frequently used to control protein–protein interactions by influen-
cing the conformation of tethering loops or a-helices or by influen-
cing the interactions of subunits (Fig. 24).
A photoswitchable peptide was designed so that its a-helical
conformation bound to the adaptor protein AP2 (Fig. 24A).95,96
This protein is important for the generation of clathrin-coated
pits for internalisation into cells. Peptides with i,i + 7 and
i,i + 11 spaced cysteine residues, whose side chains were alkylated
with 2, were able to enter cells and allowed photocontrol of
fluorescent transferrin uptake. The i,i + 7 peptide was the most
eﬀective with a 3-fold decrease in intracellular fluorescence
upon irradiation (Fig. 25). Peptide concentrations from 20 mM
to 100 mM were employed depending on the cell type.
A light-responsive cadherin molecule was created by introdu-
cing a pair of cysteine residues into the EC1 and EC2 domains
(Fig. 24B) and crosslinking them with 2.97 The resulting protein
had diﬀerent aﬃnities for calcium ions under 365 nm or white
light illumination and the half-life of the light state was strongly
aﬀected by the calcium ion concentrations. Experiments showed
Fig. 21 Cartoon of a crosslinked bZIP DNA complex. The crosslinker 2
controls the a-helicity of the coiled-coil dimerization domains, which in
turn controls the DNA binding avidity of the complex.
Fig. 22 293T cells were transfected with luciferase reporter plasmid
p(AP1-Luc) and b-galactosidase plasmid pRSV-Gal. The ratio of the activities
of the two enzymes was used to detect specific eﬀects on AP1 promotor
driven expression. Addition of non-crosslinked AFosW had a dose dependant
eﬀect as AFosW displaced native Fos from the Fos/Jun/AP-1 DNA complex.
Addition of crosslinked XAFosW has less of an eﬀect as the peptide is biased
away from its active conformation by the crosslinker, UV irradiation removes
this constraint and yields a 2-fold light-dependant inhibition of protein
synthesis. Reproduced with permission from Zheng, et al., Angew. Chem.,
Int. Ed., 2010, 49, 3943. Copyright 2010Wiley-VCH Verlag GmbH &Co. KGaA.
Fig. 23 A bromoacetate ester azobenzene used to control the relative
orientation of two basic DNA-binding helices.
Fig. 24 Cartoons illustrating the positions changed to cysteines to accept
azobenzenes in (A) AP2 b-appendage (PDB 2IV8). (B) Loop regions of
cadherin (PDB 1FF5). (C) Trans-membrane helices 2 (blue) and 7 (red) of
the SecYEG complex (PDB 1HRZ).
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a light-dependent weakening of interactions between surface
bound cadherin and irradiated crosslinked cadherins that
indicated a degree of control over dimerisation. The B-cell
leukemia-2 (Bcl-2) family of proteins, a vital part of the intrinsic
apoptosis pathway, interact through conserved helical motifs.
Photoswitchable peptides were designed based on the interact-
ing helices of Bak and Bid.98 These peptides were cross-linked
with 2 and their aﬃnity to Bcl-xL was increased by 23-fold
(i,i + 4), 20-fold (i,i + 7) and decreased by 7-fold (i,i + 11) upon
irradiation. An NMR structure of Bak i,i + 11 in complex with
Bcl-xL showed that the photoswitchable peptide bound to the
canonical BH3 binding pocket.99,100 When introduced to per-
meabilised SU-DHL-4 cancer cells, the Bak i,i + 7 peptide (7.5 mM)
proved capable of inducing light-dependent mitochondrial
membrane depolarisation and cytochrome release.101
The SecYEG complex (Fig. 24C) translocates substrates from
the cytosol to the lipid bilayer.102 Introduction of cysteine residues
and a short dibromoalkyl azobenzene crosslinker (37, Fig. 26)
facilitated control of the opening of a lateral gate from the
translocation pore to the interior of the lipid membrane. Inner
membrane vesicles containing this modified complex transported
the proOmpA pre-protein in a reversible, light-responsive manner.
Calmodulin moderates many calcium-dependent cellular
signalling events. Ten calmodulin mutants incorporating cysteines
at positions that might interfere with calcium binding sites were
constructed and then reacted with 38 (Fig. 26).103 The most
successful allowed 4-fold photocontrol of its binding aﬃnity for
its binding partner presented in a fluorescent fusion-protein.
Control of subunit interactions was demonstrated using restric-
tion endonucleases. Bis-maleimidoazobenzene 39 (Fig. 27) was
used to photo-regulate the restriction enzyme PvuII with a 16-fold
change in endonuclease activity upon irradiation; this was achieved
through regulation of the turnover number rather than a change of
the Michaelis constant.104,105
The DNAmethyltransferase SsoII was also modified to include
cysteine residues and reacted with 39, which led to a 2-fold
change of activity in response to light due to a 4-fold reduction
in KM.
106 The more subunits that are present in a complex, the
greater the changes caused by irradiation; control of the relative
orientations of the subunits of a group II chaperonin using
39 resulted in structural changes that were large enough to be
detected by cryo-electron microscopy (Fig. 28).107
Fig. 25 HeLa cells incubated with Alexa647 labelled transferrin and acid-
washed show internalisation in (a) the absence of peptide, but (b) the
protein remains surface bound when the cells are treated with TL-1,
an inhibitor peptide with i,i + 11 spaced cysteines crosslinked with 2.
(c) Irradiation of TL-1 with 380 nm light decreases uptake inhibition, but
the degree of photocontrol is significantly greater for TL-2 which has i,i + 7
spaced cysteines crosslinked by 2. The diﬀerent cysteine spacing reverses
the direction of the photocontrol with respect to TL-1. Reproduced with
permission from Nevola, et al., Angew. Chem., Int. Ed., 2013, 52, 7704.
Copyright 2013 Wiley-VCH Verlag GmbH & Co. KGaA.
Fig. 26 A bisbromoalkyl azobenzene (37) used to control the SecYEG
complex of E. coli and a maleimidoazobenzene (38) used to modify
calmodulin to insert a pendant photoswitchable group.
Fig. 27 A bis-maleimide used to control homodimeric PvuII complexes
and mixed P2X receptor complexes.
Fig. 28 15–19 Å single-particle cryo-electron microscopy reconstructions
of an a homooligomeric chaparonin whose subunits are crosslinker with 39.
Adapted by permission from Macmillan Publishers Ltd: Nat. Nanotechnol.,
2013, 8, 928, copyright 2013.
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Control of cellular uptake
Photocontrol over the uptake of a peptide by cells was demon-
strated by sandwiching azobenzene 40 (Fig. 29) between oligo-
arginine and oligo-glutamate sequences.108 Z-40 allows the
glutamates to mask the cationic polyarginine cell transduction
sequence while E-40 forces a conformational change that reveals
the cell-penetrating sequence, resulting in a 10-fold increase in
cellular uptake by HeLa cells incubated with the fluorescently
labelled peptide (1 mM) (Fig. 30).
The para-alkylthio azobenzene 41 was included between two
nuclear localising signal peptides during solid phase synthesis.109
The para-sulphur atom red-shifted the p–p* transition to 377 nm,
which is higher than the wavelength observed with an equivalent
ether (360 nm) but lower than for a para secondary amine
substituent (429 nm). A polyproline spacer and fluorophore
were added and when the resulting molecule (120 nM) was
incubated with HeLa cells the dark state was taken up more
efficiently than after light activation (Fig. 31).
Photopharmacology
Much work in photopharmacology is currently focused on creating
molecules that can produce changes in cell behaviour.110 Such
photopharmaceuticals allow increased activity at locations speci-
fied by irradiation to increase the eﬀective therapeutic concen-
tration range. For example, incretin glucagon-like peptide 1 can
have beneficial eﬀects on both the brain and the pancreas but
can also cause numerous side eﬀects elsewhere in the body.
Introducing azobenzene 42 (Fig. 32) between two helical structural
elements resulted in a peptide capable of controlling calcium ion
fluxes in pancreatic beta cells and moderating insulin secretion
in response to light (Fig. 33).111 Despite the power of modifying
natural systems for photocontrol by identifying critical elements
and controlling the conformation of the corresponding peptides,
the properties of peptides are not always ideal for their use as
therapeutics. An increasing number of small molecule drugs have
been modified to include azobenzenes to provide photoswitching
functionality. Small molecule 43 (Fig. 32) targets the same
glucagon-like peptide 1 pathway as the peptide modified with
42111 and yields similar levels of photocontrol of insulin secretion
without a being linked to a peptide.112
The stilbene element of combrestatin A4 (44), a cytotoxic
experimental drug to treat advanced cancers, was replaced by
azobenzene to yield 45.113–115 While E-45 is an extremely poor
Fig. 29 A sterically hindered push–pull azobenzene used to photocontrol
cell uptake of a fluorescently labelled peptide.
Fig. 30 HeLa cells incubated with rhodamine B (Asp)9-40-(Arg)9 after
(a) UV light irradiation (1 mM) and (b) blue light irradiation. Adapted under
CC-BY 3.0 from Prestel and Mo¨ller, Chem. Commun., 2016, 52, 701.
Fig. 31 Azobenzene amino acid derived from thioglycolic acid. The para-
alkylthio substituent red-shifts the azobenzene absorbance to 377 nm.
Fig. 32 Azobenzene amino acid that when incorporated into the back-
bone of a incretin peptide could control b-turns formation and insulin
secretion and a small molecule capable of the same feat without a peptide
component.
Fig. 33 (a) Insulin secretion from pancreatic beta cells in response to
glucose (8mM, G8), a liraglutide-derived peptide (Lira) and the same peptide
with 42 incorporated in its dark (trans-LirAzo) and UV light irradiated
(cis-LirAzo) states. Adapted under CC-BY from Broichhagen, et al., Angew.
Chem., Int. Ed., 2015, 454, 15565.
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inhibitor of tubulin polymerisation (effective growth arrest
at 25 mM in an cell proliferation assay), Z-45 (100 nM) is only
tenfold less effective than 44 (10 nM) such that irradiation with
400 nm light causes effective photoswitching and a 200-fold
change in cytotoxicity of the drug (Fig. 34 and 35).114 45 and
similar photostatins can induce mitotic arrest and cell death in
Jurkat, HEK, HeLa andMDA-MB-231 cells.113 ‘Mitotic catastrophe’
could be selectively induced on an individual cell level in an
impressive display of non-selective drug delivery coupled with
light-driven activation. The same strategy was successfully applied
to the synthesis of a range of histone deacetylase inhibitors
exemplified by 46116 and 47117 and a photoresponsive version of
the antibiotic ciprofloxacin 48 (Fig. 36).118
Azobenzene was also incorporated into acyl homoserine
lactones to create a photoswitchable quorum sensing signalling
molecule (49) (Fig. 37).119 When irradiated, 49 is five-fold more
eﬀective at activating the promoter of virulence genes in
P. aeruginosa; its light-state has a half-life of 2.5 hours at
37 1C (Fig. 35).
Control of ion channels
The application of photoswitchable ligands to control ion channels
is a remarkable success story.120 The first examples of photoswitch-
able channels were synthetic gramicidin derivatives,121–126 but
attention soon turned to the many ligand-gated ion channels that
adorn the outer membrane of cells. Initial experiments showed
that azobenzene-containing molecules could mimic the natural
ligands for such channels,127 leading to the development of two
distinct methodologies. In the first a channel blocking ligand
mimic group is tethered to an ion channel by an azobenzene-
containing linker so that irradiation either leads to insertion or
removal of a blocking group from the channel128,129 or binding at a
distal site that induces structural changes in the channel. The
second approach uses less specific freely diffusible ligand mimics.
Tethering is most conveniently achieved through the introduction
of cysteine residues at solvent exposed positions on receptor
proteins and reacting their side chains with maleimides where
the use of different cysteine positions allows the tuning of the
response to photoswitching.130 The genes for individual subunits
of heteromeric pores can be altered and heterologously expressed
to create hybrid receptors. The function of individual receptor
subtypes can then be mapped by their selective activation with
light.5,131–135
The tethered photoswitchable ligand 50 was applied to the
voltage-gated potassium ion channel Shaker by selectively con-
jugating it to a loop on the rim of the pore. Whilst the extended
E-50 form is long enough to allow the pendant ethylammonium
group to block the pore, the photo-activated Z-50 is too short
(Fig. 38 and 39). Z-50 leaves the pore open allowing action
potentials to be silenced by blocking potassium ion transport136
or, with furthermutations to allow sodium influx, action potentials
to be triggered by irradiation.137 Use of less selective acrylamide,
chloroacetate or epoxide agents allowed the non-selective labelling
Fig. 34 The antitumour natural product combrestatin A4 and an azo-
benzene containing analogue.
Fig. 35 Cremaster muscle cells of live C57BL/6 mice superfused for
40 minutes with 50 mM 45-O-phosphate (a soluble prodrug) (a) in the
dark (left) or (b) under 390 nm light irradiation. Samples were then excised
and stained for a-tubulin (yellow) and nuclei (red). Scale bars 15 mM.
Adapted with permission from Borowiak, et al.,Cell, 2015, 162, 403. Copyright
2015 Cell Press.
Fig. 36 An azobenene containing histone deacetylase inhibitor and a peri-
pherally azobenzene-modified derivative of ciprofloxacin.
Fig. 37 Azobenzene-containing molecule used to mimic naturally occurring
homoserine lactone molecules use by bacteria for quorum sensing.
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of endogenously expressed Shaker channels to create UV
responsive cultured neurons.138 Viral co-transduction of DNA
encoding mutant channels and GFP into the hippocampal
region of mice caused no visible behavioural changes.139
To complement diﬀusible azobenzene-containing glutamate
mimics,140,141 the photoswitchable tethered ligand 51 (Fig. 40)
was applied to ionotropic glutamate receptors, which feature
extracellular binding sites that cause conformational changes
Fig. 38 A photochromic, tethering ligand optimised to control a mutant
Shaker ion channel with a carefully positioned cysteine residue near the
binding pocket for positively charged groups.
Fig. 39 (a) UV/visible absorbance spectra of 50 conjugated to glutathione.
(b) Action spectra of inside-out membrane patches containing Shaker ion
channels conjugated with 50. Adapted by permission from Macmillan
Publishers Ltd: Nat. Neurosci., 2004, 7, 1381, copyright 2004.
Fig. 40 Azobenzene-containing photoswitchable tethering ligands for
ionic glutamate receptors. Replacing the amido substituent with an amino
substituent creates a red-shifted, fast-relaxing switch.
Fig. 41 (a) Representative action spectrum showing activation of the
homotetrameric kainite receptor GluK2(439C) with 52 conjugated to the
its ligand binding domain. (b) An action spectrum of the same protein
conjugated with 53 showing how these two tethered ligands might be
used in parallel. (a) Adapted with permission from Kienzler, et al., J. Am.
Chem. Soc., 2013, 135, 17683 and Copyright 2013 American Chemical
Society. (b) Adapted under CC-BY from Rullo, et al., Chem. Commun.,
2014, 50, 14613.
Fig. 42 A tetra-ortho-chloroazobenzene photoswitchable tethered ligand.
The n–p* absorbance band separation allows this molecule to be switched
with light up to 625 nm at high intensities.
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when populated by glutamate.142–146 Zebrafish larvae engineered
to express modified channels were bathed in a solution of 51
for 30 minutes. Touching the treated larvae revealed reversibly
altered behaviour according to the irradiation they had received;
365 nm light deactivated their escape reflex and 488 nm light
reactivated it.147,148 Channels in five-day-old zebrafish weremodi-
fied with 51 to elucidate the function of Kolmer–Agduhr cells,
demonstrating the potential of this technique as an exquisitely
selective investigative tool.149 In addition to pure ligand gating
approaches, bis-maleimide (39) has been used to control the
trimeric proteins that comprise P2X2/3 receptors moving the
subunits apart to open the pore.150
An exciting long-term research goal is the use of these
channels to achieve a degree of sight restoration for vision-
impaired patients, which requires rapid relaxation and absorp-
tion at distinct wavelengths in the visible spectrum. A modified
azobenzene (52) where one ring bears an electron-releasing
amine substituent increases the channel activation wavelength
from 380 nm to 445 nm, a wavelength better suited for vision
restoration research. Channels modified with 52 returned to their
ground state 2200-fold faster than channels modified with 51,
allowing much higher temporal resolution control of neuron
firing.151 Azobenzene 52 has amuch-improved two-photon absorp-
tion cross-section that is comparable to that of fluorescent
proteins.152 A tethered tetra-ortho-chloroazobenzene glutamate
ligand (53) allowed triggering of a modified GluK2 kainate
receptor with 560 nm light.153 High intensity 625 nm light could
also be used, albeit at lower eﬃciency, but 440 nm irradiation
induced no response so that 53 and 51 can work orthogonally
with narrow wavelength light sources (Fig. 41).
A recent report describes late stage incorporation of ortho-
chloro substituents to preformed azo compounds, making such
molecules more accessible.154 Even longer wavelengths can be
used to switch 54 (880 nm) and 55 (900 nm), which were designed
for improved two-photon absorption (Fig. 42).155
Non-tethered, diﬀusible azobenzene ligands can also be used to
control a wide variety of channels. Successful endeavours include
analysing the behaviour of Purkinje cells using 56,156 modulating
insulin secretion via ATP-sensitive potassium channels with 57 and
58,157,158 versions of the transient receptor potential pain receptor
ion channel TRPV1,159 that respond to compounds including azo-
capsaicin 59,160 metabotropic glutamate receptors (class C GPCR
receptors) controlled by 60,161 trimeric amiloride-sensitive sodium
channels gated by 61,162 G-protein coupled inwardly rectifying
potassium channels regulated by 62,163 and endowment of retinal
function on blind mice using 63 (Fig. 43).164
Conclusions
Recent breakthroughs in tuning the physical properties of
photoswitches have improved the scope of existing tools, but have
also opened up new opportunities. Azobenzenes with extended
Z-isomer half-lives now cover the timescales of more complex
biological events and allow in vivo kinetics experiments to be
conducted. Control over the lifetime of active states is comple-
mented by an expanded range of photoswitching wavelength
and oﬀers the possibility to combine two or more dyes to create
multiplexed biophotonic systems. Such combinations of probes
can lead to powerful tools to study thresholds in signalling events,
as diﬀerentially timed light pulses could be used to simulate
concentration gradients. The ever-growing number of photo-
pharmaceutical tools could also be envisaged being used in pairs,
with the eﬀects of a pair of opposed molecules activated in
diﬀerent locations providing proportionally greater eﬀects.
Future challenges include improving the mechanisms
researchers use to translate photoisomerisation energy into
structural change.165–168 Natural systems have evolved to beFig. 43 Non-tethered azobenzene ligand for controlling various ion channels.
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delicately balanced to change conformation when a ligand or
binding partner is present, but directed evolution is presently
impractical for proteins containing non-proteinogenic amino
acids. Computational studies may therefore offer the best chance
of successfully (re)designing systems to achieve improved photo-
control over protein structure and function.
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